

FOR IMMEDIATE RELEASE:

Cerestim is awarded TSB grant.

London, UK – May 7th, 2014 – Cerestim Ltd is delighted to announce that it has been chosen by the UK Technology Strategy Board to receive a Biomedical Catalyst Feasibility Study grant in the latest round of their programme.

The project title is: “Feasibility assessment of the opportunity for the use of transcranial cranial stimulation for the treatment of brain disorders”. The project is expected to run from June to November of 2014.

Ian Harris, CEO, said “We are delighted to receive the award. We look forward to working with the Technology Strategy Board on the project. We feel that transcranial stimulation technology has great potential and could provide significant healthcare benefits, relieve a great deal of suffering and reduce health provider costs. We have already assembled a fantastic team to work on this project.”

Cerestim has started work on developing its scientific and commercialisation strategy; fund raising; developing academic and commercial partners and preparing IP for filing. It plans to make substantial progress on these during 2014.

The Technology Strategy Board is the UK’s innovation agency and part of the Department for Business Innovation & Skills. More information can be found on: <https://www.innovateuk.org/biomedical-catalyst>

Contact:

Ian Harris
ian.harris@cerestim.com

###